US court orders Eli Lilly to pay royalties on diabetes drugs
Eli Lilly is experiencing judicial headwind in the US, as a federal court has ordered the Novo Nordisk competitor to pay royalities from insulin sales to an Arizonan firm.
BY ANDREAS LØNSTRUP, TRANSLATED BY DANIEL PEDERSEN
Eli Lilly owes an Arizonan company royalties from insulin product sales, a US court has ruled, as reported by news organization Endpoint News. A trial is now likely.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg&w=384&q=75)
